Skip to main content

Drug Interactions between fosphenytoin and vigabatrin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

fosphenytoin vigabatrin

Applies to: fosphenytoin and vigabatrin

Coadministration with vigabatrin may modestly decrease the plasma concentrations of phenytoin. The exact mechanism of interaction is unknown, although in vitro drug metabolism studies indicate that it may involve induction of CYP450 2C isoenzymes in some patients. A gradual reduction of 16% to 33% in phenytoin plasma levels has been reported in controlled clinical studies of vigabatrin. These changes are unlikely to be of therapeutic significance in most patients, and phenytoin dose adjustments are not routinely required. However, a dose adjustment should be considered if an interaction is suspected.

References (5)
  1. Tassinari CA, Michelucci R, Ambrosetto G, Salvi F (1987) "Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy." Arch Neurol, 44, p. 907-10
  2. Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Napoliello MJ, Sherry KM, Szabo GK (1987) "Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up." Neurology, 37, p. 184-9
  3. Rimmer EM, Richens A (1989) "Interaction between vigabatrin and phenytoin." Br J Clin Pharmacol, 27(suppl 1, s27-33
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  5. (2009) "Product Information. Sabril (vigabatrin)." Lundbeck Inc

Drug and food interactions

Moderate

vigabatrin food

Applies to: vigabatrin

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer